Tilray Brands (NASDAQ: TLRY) has shed roughly 50% of its value in 2026, even as the company reports its best-ever fiscal revenue figures.
The cannabis-turned-consumer-goods company generated record revenues of $915 million in fiscal 2026, alongside record gross profit, marking a significant operational milestone.
Despite those headline numbers, the stock continues to trade below $5, reflecting deep investor skepticism about the company’s path to profitability.
Tilray originally attracted attention as a marijuana company, riding the wave of investor enthusiasm for cannabis stocks before that sector dramatically collapsed.
Management has since pivoted, positioning Tilray as “a global lifestyle and consumer packaged goods company leading at the nexus of the beverage, cannabis, and wellness industries.”
The strategy involves building out a portfolio of alcoholic beverages, CBD-infused products, and branded consumer goods to reduce dependence on cannabis revenue.
Tilray recently expanded its craft beer footprint through the acquisition of BrewDog, adding another consumer brand to its growing portfolio.
Revenues increased across all business segments in fiscal 2026, suggesting the operational pivot is gaining traction and management is executing reasonably well.
However, the company still reported a loss of $1.09 per share in fiscal 2026, which, while dramatically better than the $24.56-per-share loss in fiscal 2025, keeps profitability out of reach.
To understand the scale challenge facing Tilray, consider that Coca-Cola (NYSE: KO) generated $13.4 billion in sales in the second quarter of 2026 alone, more than 13 times Tilray’s full-year record revenue.
Tilray’s current market capitalization sits at approximately $600 million, making it a very small player in the highly competitive consumer packaged goods space.
Scale matters enormously in consumer staples, where distribution networks, marketing budgets, and research and development costs can create meaningful competitive barriers.
The company’s relatively small size makes it difficult to differentiate its brands against larger, better-resourced peers across alcoholic beverages and wellness products.
Until Tilray demonstrates it can convert record revenues into consistent profits, the broader investing public is unlikely to revisit the stock with any enthusiasm.
Analysts and commentators agree the stock remains suitable only for aggressive, risk-tolerant investors who are comfortable with ongoing losses during a major business transformation.
For those unwilling to take on that level of risk, keeping Tilray on a watch list while waiting for evidence of sustained profitability may be the more prudent approach.
